Seer to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Seer (Nasdaq: SEER) will participate in the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026. Management will take part in a fireside chat at 11:10 a.m. ET, with a live webcast and archived replay available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – SEER
On the day this news was published, SEER gained 2.48%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $110M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SEER is up 1.49% while two momentum-screened biotech peers are down (median -1.6%), suggesting today’s strength is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-02-05 | Earnings date notice | Neutral | +2.3% | Announced timing and webcast details for Q4 and full-year 2025 results. |
| 2025-12-01 | Scientific validation | Positive | -1.0% | Nature Genetics study validating Proteograph for large-scale proteomics and biomarker discovery. |
| 2025-11-07 | Conference data update | Positive | -3.2% | HUPO 2025 presentations highlighting translational power of deep proteomics across diseases. |
| 2025-11-06 | Quarterly earnings | Positive | -0.5% | Q3 2025 results with revenue growth, 51% gross margin and reiterated 2025 guidance. |
| 2025-10-29 | Investor conferences | Neutral | -3.1% | Planned participation in UBS and Canaccord November investor conferences with webcasts. |
Recent positive scientific and earnings updates have often seen negative next-day price moves, while scheduling/participation announcements show mixed to negative reactions.
Over the last few months, Seer has mixed operational and investor-relations news. It scheduled Q4 and full-year 2025 results for February 26, 2026, which saw a modest +2.29% move. Positive scientific validation, including a Nature Genetics study and broad HUPO 2025 data, drew next-day moves of -1.04% and -3.24%. Q3 2025 results with revenue growth and reiterated $17–$18 million guidance led to a -0.46% reaction. Prior conference participation news on October 29, 2025 saw shares down 3.06%, framing today’s conference update in a cautious historical context.
Market Pulse Summary
This announcement highlights Seer’s participation in the TD Cowen 46th Annual Health Care Conference, with a fireside chat on March 4 and both live and archived webcasts. Historically, the company has paired scientific updates and earnings with active investor communication through calls and conferences. Investors following the story may focus on what management discusses regarding recent financial results, platform adoption, and strategic priorities during the 11:10 a.m. ET session.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 4th at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Inquiries:
investor@seer.bio
FAQ
When will Seer (SEER) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch Seer (SEER) at the TD Cowen conference on March 4, 2026?
Will Seer (SEER) provide a replay of its TD Cowen 2026 presentation?
What is the expected format of Seer’s (SEER) participation at TD Cowen 46th Annual Health Care Conference?
Where is the TD Cowen 46th Annual Health Care Conference where Seer (SEER) will appear?
Does Seer (SEER) require registration to view the TD Cowen conference webcast on March 4, 2026?
